Asuragen

Asuragen is a private, commercial-stage molecular diagnostics company that has been delivering standardized testing kits to clinical and research laboratories since its founding in 2006. The company's core business revolves around simplifying complex molecular tests, particularly in genetics and oncology, through ready-to-use kits and reagents. It operates in the growing in-vitro diagnostics (IVD) market, serving labs that require robust, reproducible assays. Asuragen's strategy is built on a portfolio of analytically validated products that aim to improve testing accessibility and efficiency.

Assay development and standardization platform for PCR-based molecular diagnostics, focusing on qPCR and dPCR kits, reference materials, and associated bioinformatics.

Asuragen competes in the molecular diagnostics segment against large, diversified players like Roche, Qiagen, Abbott, and Bio-Rad, as well as numerous specialty diagnostic companies. Its differentiation lies in its focus on converting complex assays into standardized, user-friendly kits for clinical labs, a niche between raw reagents and fully automated instruments.